News

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray
New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Phar ...